Previous 10 | Next 10 |
Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19 PR Newswire FORT COLLINS, Colo. , Feb. 16, 2021 /PRNewswire/ -- Cytocom, Inc. , a leading biopharmaceutical company creating first second...
New solutions enable enhanced delivery, tracking and management of drug safety reporting and medical questions from sites ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industr...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Dr. Steve Cutler, CEO of ICON plc, & Mr. Bre...
Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device ...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced the release of its first Environmental, Social and ...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Mr. Brendan Brennan, CFO of ICON plc, will prese...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2020 Q3 earnings call. For further details see: ICON Public Limited Company 2020 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Icon PLC (NASDAQ: ICLR) Q3 2020 Earnings Call Oct 22, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Icon PLC (ICLR) Q3 2020 Earnings Call Transcript
ICON Public Limited Company (ICLR) Q3 2020 Earnings Conference Call October 22, 2020 09:00 AM ET Executives Jonathan Curtain - VP Corporate Finance & IR Steve Cutler - CEO Brendan Brennan - CFO Analysts David Windley - Jefferies Patrick Donnelly - Citigroup Elizabeth Anderson - Evercore R...
Icon (ICLR): Q3 GAAP EPS of $1.72 beats by $0.12.Revenue of $701.73M (-1.2% Y/Y) beats by $31.63M.Raising FY 2020 revenue guidance to a range of $2,750-$2,810M and EPS in the range of $6.35-$6.50.Shares +4.83%.Press Release For further details see: Icon EPS beats by $0.12, beats on reve...
News, Short Squeeze, Breakout and More Instantly...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...